These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19482212)

  • 1. Prasugrel STEMI subgroup analysis.
    Shil AB; Strohm MP
    Lancet; 2009 May; 373(9678):1846; author reply 1846-8. PubMed ID: 19482212
    [No Abstract]   [Full Text] [Related]  

  • 2. Prasugrel STEMI subgroup analysis.
    Floyd J; Wolfe S
    Lancet; 2009 May; 373(9678):1845-6; author reply 1846-8. PubMed ID: 19482209
    [No Abstract]   [Full Text] [Related]  

  • 3. Prasugrel STEMI subgroup analysis.
    Webster MW; Gladding P
    Lancet; 2009 May; 373(9678):1846; author reply 1846-8. PubMed ID: 19482210
    [No Abstract]   [Full Text] [Related]  

  • 4. Prasugrel versus clopidogrel.
    von Lewinski F; Riggert J; Paulus W
    N Engl J Med; 2008 Mar; 358(12):1299; author reply 1299-301. PubMed ID: 18357639
    [No Abstract]   [Full Text] [Related]  

  • 5. TRILOGY ACS: prasugrel of benefit only after angiography?
    Swaminathan RV; Feldman DN
    Lancet; 2013 Aug; 382(9892):580-2. PubMed ID: 23953376
    [No Abstract]   [Full Text] [Related]  

  • 6. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
    Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38".
    Serebruany VL
    Circulation; 2010 Aug; 122(8):e436; author reply e437. PubMed ID: 20733108
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
    Wiviott SD; de Lemos JA
    Am Heart J; 2007 Oct; 154(4):603-6. PubMed ID: 17892976
    [No Abstract]   [Full Text] [Related]  

  • 9. Prasugrel versus clopidogrel.
    Serebruany V
    N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensifying platelet inhibition--navigating between Scylla and Charybdis.
    Bhatt DL
    N Engl J Med; 2007 Nov; 357(20):2078-81. PubMed ID: 17982183
    [No Abstract]   [Full Text] [Related]  

  • 11. Can we override clopidogrel resistance?
    Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
    Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prasugrel or clopidogrel in patients with coronary intervention].
    Schrör K
    Internist (Berl); 2009 Nov; 50(11):1293-6. PubMed ID: 19830398
    [No Abstract]   [Full Text] [Related]  

  • 13. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 14. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
    Wiviott SD; Braunwald E; Murphy SA; Antman EM;
    Am J Cardiol; 2008 May; 101(9):1367-70. PubMed ID: 18435974
    [No Abstract]   [Full Text] [Related]  

  • 15. A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
    Heart Advis; 2010 May; 13(5):6. PubMed ID: 22816152
    [No Abstract]   [Full Text] [Related]  

  • 16. Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
    Solomon S; Vacek JL
    Postgrad Med; 2010 Jan; 122(1):198-200. PubMed ID: 20107305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
    Wiviott SD; White HD; Ohman EM; Fox KA; Armstrong PW; Prabhakaran D; Hafley G; Lokhnygina Y; Boden WE; Hamm C; Clemmensen P; Nicolau JC; Menozzi A; Ruzyllo W; Widimsky P; Oto A; Leiva-Pons J; Pavlides G; Winters KJ; Roe MT; Bhatt DL
    Lancet; 2013 Aug; 382(9892):605-13. PubMed ID: 23953385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test before you stop.
    Kumar A; Roberts DH
    Arch Surg; 2009 Aug; 144(8):787; author reply 787. PubMed ID: 19687387
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
    Gurbel PA; Erlinge D; Ohman EM; Neely B; Neely M; Goodman SG; Huber K; Chan MY; Cornel JH; Brown E; Zhou C; Jakubowski JA; White HD; Fox KA; Prabhakaran D; Armstrong PW; Tantry US; Roe MT;
    JAMA; 2012 Nov; 308(17):1785-94. PubMed ID: 23117779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel versus prasugrel: times are changing, but not for everyone.
    Dobesh PP
    Pharmacotherapy; 2009 Dec; 29(12):1393-6. PubMed ID: 19947798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.